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Introduction. Sanitary tampons have been in existence for over 
60 years. Their use may present certain health risks, potentially 
associated with an abnormal change of microbial flora in the 
vagina (e.g., toxic shock syndrome). Tampon production and mar-
keting are regulated differently in different countries. In Australia, 
Canada and the USA, tampons are classified as Class-II medi-
cal devices and their marketing requires pre-clinical and clinical 
studies, including microbiological trials. In Europe, tampons are 
considered consumer products and safety-related data are pro-
vided only if the manufacturer deems them to be useful. Sterility 
of these products is not requested by law; thus they may represent 
a potential vehicle for microorganisms. Due to the lack of data 
on microbial characteristics of tampons, an analytical investiga-
tion was carried out to characterize and quantify the microbial 
flora present on sealed tampons of various brands present on the 
market in Italy.
Methods. Traditional cultural methods were used to characterize 
and quantify bacteria and fungi. Identification of colonies was 
performed with biochemical techniques.
Results. Results showed low microbial concentrations in 93% of 
the positive samples. A rare presence of opportunistic pathogens 
was detected and a few samples (6%) were characterized by bac-
terial species of human origin.
Conclusions. In the light of these data, the examined tampons 
were found to have good hygienic quality. Nevertheless, to mini-
mize the microbial risks linked to the use of these products, strict 
hygienic rules during their production and manipulation have to 
be adopted.
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Introduction
The introduction on the international market of sanitary 
towels, also known as internal tampons, dates back to 
the thirties of the last century. The spread of tampon use, 
initially slowed by misinformation and some initial in-
juries, had a dramatic increase once its advantages over 
conventional sanitary tampons became apparent. The 
reassurance of freedom of movement in performing all 
types of work and sports during menstruation, combined 
with their protection and comfort are the characteristics 
that for over sixty years encouraged many women to use 
these products.
The function of the internal tampon is to absorb men-
strual blood inside the vagina after it has left the uterus, 
preventing it from leaking out, and thus providing suit-
able protection with total discretion. The differences in 
the use of external tampons requires some knowledge of 
female genital tract anatomy for the tampon to be prop-
erly positioned, a prerequisite in ensuring total absorp-
tion. The choice available between the different tampon 
types with different absorption characteristics depends 
on the required level of protection, according to differ-
ent needs. 
Currently, internal tampons usually consist of an ab-
sorbent cellulose material and plastic derived material. 
They can be wrapped by a thin non-woven fabric layer 
and, at times, with an applicator in plastic or cardboard, 
and a cotton, polyethylene or viscose string for extrac-
tion [1]. These products are not requested to be sterile.
Over the years there were some problems related to the 
use of tampons, some, less serious, being vaginal dryness 
and ulcerations of the vagina, usually associated with the 
use of tampons with absorbency higher than the required 
needs [2]. Far more important however, the Toxic Shock 
Syndrome (TSS) can appear as a severe toxemia, some-
times rapidly becoming fatal. Its symptoms are high 
fever, vomiting, diarrhea, confusion and rash  [3]. The 
disease is caused by the Staphylococcus aureus toxin 1 
(TSST-1), bacterium that commonly colonizes nose and 
vagina  [4]. The women most at risk of TSS are those 
with an earlier colonization of the vagina, regularly us-
ing tampons. It is likely that mechanical or chemical fac-
tors related to the use of tampons favor an increase of the 
bacterial toxin production which enters the bloodstream 
through the disruption of the mucosa [5]. The incidence 
of this disease in women has rapidly decreased follow-
ing massive advertising campaigns on the role of the 
tampons and diaphragms, and after the withdrawal of 
some brands of tampons from the market  [6]. Accord-
ing to recent estimates, the incidence of the disease is 
3 cases per 10,000 menstruating women [7]. Moreover 
there is evidence that in some cases this also occurs in 
women not using tampons, and also in the post-operative 
MICROBIAL SAFETY OF COMMERCIAL TAMPON
E227
period and post-partum situations  [8]. During use, the 
risk was related mainly to prolonged times of use (more 
than eight hours) [9]. Based on the results of some re-
searches, an increase of glucose concentration, due to ly-
sis of the carboxymethyl cellulose by the microbial flora 
of the vagina, can support the growth of S. aureus [10].
Regulations on production and marketing of tampons dif-
fer across countries, and are stricter in Canada, Australia 
and the United States [11, 12]. Internationally, there is 
no legislation providing for sterility requirements. 
In the United States these products are classified as 
Class II medical devices. Special controls are required, 
and their put on the market is subject to the approval 
of the Food and Drug Administration [12]. In addition 
to requirements for shape, size, composition, absorption 
capacity and presence of chemical residues, the manu-
facturer must perform pre-clinical toxicological and 
microbiological tests. Particularly, for microbiological 
safety requirements, the manufacturer must demonstrate 
that the product does not favor the growth of S. aureus, 
does not stimulate the production of TSST-1 toxin, and 
does not alter the normal vaginal microbial flora. Clini-
cal studies are also required if the products have new 
types of buffers, or when there are significant changes in 
the design and material used, compared to the traditional 
sold tampons [12].
In the European Union, tampons are not considered 
medical devices and therefore are not regulated as such. 
The producer can decide whether clinical trials are re-
quired to verify the safety of the product  [13,  14]. In 
Italy, tampons, as other products for feminine hygiene, 
are consumer goods, and the safety obligations of the 
manufacturer and distributor are defined by the Con-
sumer Code [15].
Given the mode of use, as well as providing a possible 
growth support for the microorganisms present on vagi-
nal mucosa, tampons can be a vehicle of exogenous mi-
croorganisms in the female genital apparatus. 
Numerous clinical studies have been performed to char-
acterize the microbial vaginal flora during menstruation 
and to evaluate any change of its composition associated 
with the use of tampons [16, 17]. Many studies have also 
focused on the possible role of the chemical components 
of tampons as a potential support for microbial growth 
[10, 18]. Instead, currently, no data exist to estimate the 
possible impact in terms of the microbial concentration 
and type of species conveyed by non-sterile exogenous 
devices on the vagina.
Therefore an analytical investigation was performed 
to quantify and characterize the microbial flora pre-
sent on tampons of various brands present on the Ital-
ian market.
Methods
Fifteen brands of sealed internal tampons from five ma-
jor manufacturers were subjected to microbiological 
analysis. The products were aseptically removed from 
their packaging, immersed in 100 mL of buffered saline 
solution added and stirred on a rotary plate for 2 minutes. 
The concentrated eluate was divided into several aliquots 
and the analyses were performed using the membrane 
filtration technique. Eight different groups of microor-
ganisms/bacterial species were investigated. Thus, the 
membranes were incubated on various agarized media 
for the detection of the following microbial parameters:
• Mesophilic bacteria. Incubation on Plate Count Agar 
(Oxoid/ThermoFisher, USA) at 36°C for 72  h; the 
count of all colonies was made.
• Fungi (molds) and yeasts. Incubation on Sabouraud 
Destrose Agar (ThermoFisher Diagnostics, USA) at 
25°C for 7-10  days; mold and yeast colonies were 
counted.
• Anaerobic Bacteria. Incubation on Plate Count Agar 
(ThermoFisher Diagnostics, USA) at 36°C in anaer-
obiosis for 72 h; the count of all colonies was made.
• Coliforms. Incubation on C-EC (Biolife, Italy) at 
36°C for 24 h; blue colonies were counted.
• Escherichia coli. Incubation on C-EC (Biolife, Italy) 
at 36°C for 24 h; blue and fluorescent colonies were 
counted using a Wood lamp.
• Staphylococcus spp. Incubation on Baird Parker 
(ThermoFisher Diagnostics, USA) at 36°C for 48 h; 
the count of black colonies was made.
• Candida albicans. Incubation on Biggy Agar (Ther-
moFisher Diagnostics, USA) at 36°C for 18-72  h; 
dark brown colonies were counted.
• Pseudomonas aeruginosa. Incubation on Pseu-
domonas Agar/CN (ThermoFisher Diagnostics, 
USA) at 36°C for 48 h; the count of green-blue colo-
nies was made, and a biochemical confirmation of 
fluorescent and reddish brown colonies using a Wood 
lamp was performed.
Biochemical identification: the grown bacterial colonies 
were isolated and identified by the miniaturized system 
VITEK® 2 Compact (Biomerieux, France).
Results
From the 15 tampons examined, only one did not show 
microbial growth, while 93% of the samples exhibited a 
moderate bacterial load (Tab. I). A maximum of 100 cfu/
tampon for the mesophilic bacteria and 55 cfu/tampon 
for anaerobic bacteria were counted, respectively. Molds 
were detected in 27% of the tampons, and the highest 
mold load did not exceed 15  cfu/tampon. Yeasts were 
absent in all samples. None of the examined tampons 
showed contamination by the fecal bacterial indicators, 
E. coli and Coliforms. The species P. aeruginosa and S. 
aureus were also absent in all samples, as well as Can-
dida albicans. 
From all the positive samples for the mesophilic bacte-
ria, species belonging to the genus Bacillus were iso-
lated. Bacteria of the genus Alicyclobacillus were also 
identified in one sample, and in 50% of the samples, 
Staphylococcus epidermidis and Micrococcus luteus 
were detected (Tab. II).
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Discussion and conclusions
As well as other parts of the human body, the vagina is 
populated by numerous microorganisms which together 
constitute the vaginal microbiome. This ecosystem is 
typical model of well-organized balanced mutualistic 
consortium. The indigenous bacterial communities play 
a protective role in preventing colonization of host by 
opportunistic pathogens.
Lactobacillus is the dominant vaginal bacterial genus 
and, to a lesser extent, streptococci, enterobacteria, 
staphylococci, corynebacteria, anaerobic bacteria, Gard-
nerella, Candida and Mycoplasma even colonize this 
district. Some of these, whilst being potential pathogens, 
do not represent a real health risk, unless their concentra-
tions increase in a non-proportional manner, attributable 
to imbalances due to various causes. Given the lack of 
sterility, potential inadequate measure of hygiene during 
the insertion, anatomical proximity of the genito-urinary 
system and intestinal apparatus, the use of internal tam-
pons could be a potential vehicle for microorganisms. 
However, the data obtained from the quantification and 
characterization of the microbial populations of these 
products showed not high concentrations of bacteria and 
molds. 
As for the composition of the microbial flora present 
onto these products, the most common microorgan-
isms were bacteria belonging to the genus Bacillus, 
known to be present ubiquitously in nature, to produce 
endospores, to be capable of withstanding particularly 
hostile environmental conditions. The isolated species 
from tampons, namely B. subtilis, B. circulans, B. li-
cheniformis and B. pumilus, are not generally associated 
with pathological conditions, although the latter two 
have been reported as agents responsible for diseases in 
immunocompromised individuals [19].
Staphylococcus spp. and Micrococcus spp. were also 
isolated. Species belonging to these genera are common 
in human environments and on human body. In particu-
lar, Staphylococcus epidermidis is a member of the nor-
mal human cutaneous and mucosal flora and represents 
the 65-90% of all staphylococci that usually inhabit 
skin, vagina, urethra and mouth. In physiological condi-
tions, the bacterium does not harm the host. However, 
in an impaired immune condition (undergoing surgical 
implants or transplants etc.), this species can become a 
commensal opportunistic pathogen, causing disease in 
immunocompromised and catheterized individuals [20]. 
Even Micrococcus luteus is part of the skin microbiome 
of mammals and is a ubiquitous species in the environ-
ment. It is not considered a pathogen, but an opportunist 
bacterium, responsible for skin infections, endocarditis, 
septicemia and septic shock [21].
Taking into account both the scattered detection of the 
bacterial species of human origin (6% of the samples) 
and their low microbial loads, the presence of these bac-
teria in the examined sealed internal tampons may not 
constitute a health risk to the consumer. Only in specific 
host immune debilitation conditions and at high concen-
trations these microorganisms can perform their patho-
genic action. This aspect was taken into consideration 
when 1400 tampons were recalled because the company 
tests detected Chronobacter sakazakii on the plastic tub-
ing [22]. In fact, this bacterium, responsible of vaginal 
and urinary tract infections, pelvic inflammatory diseas-
es or other potentially life-threatening infections, repre-
sents a higher risk in immunosuppressed women.
In view of our results, for minimizing the risks of the 
microbial origin, next to strict hygienic rules during pro-
duction and packaging of these products, the observance 
of good practices (e.g., hand washing) during their use 


















1T 10 < 1 < 1 5
2T 20 5 < 1 < 1
3F 100 10 < 1 < 1
4N 100 5 < 1 < 1
5O 40 15 15 < 1
6C 5 < 1 55 < 1
7C 20 < 1 < 1 < 1
8O 10 < 1 < 1 < 1
9T 10 5 < 1 < 1
10V 5 < 1 < 1 < 1
11O 100 < 1 5 < 1
12T 10 < 1 < 1 < 1
13L 100 < 1 < 1 < 1
14T 5 10 < 1 < 1
15T < 1 < 1 < 1 < 1
CFU: Colony Forming Unit
Tab. II. Bacterial species identified from the analysed tampons.



























MICROBIAL SAFETY OF COMMERCIAL TAMPON
E229
and manipulation has to be adopted for reducing poten-
tial allochthonous contamination.
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